CommercialPrior AuthMedium impact
Drug Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Dermatology, Allergy & Immunology, Family Medicine +2 more·Pharmacy
Effective date
May 1, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross changed prior authorization criteria for Ebglyss (atopic dermatitis medication) effective May 1, 2026. Patients must now fail BOTH a topical calcineurin inhibitor AND a topical corticosteroid before Ebglyss will be covered, replacing the previous single topical therapy failure requirement.
Action Required
Before May 1, 2026: Providers prescribing Ebglyss must document patient failure of both a topical calcineurin inhibitor AND a topical corticosteroid in medical records. Update prior authorization request forms to include documentation of both medication failures. Claims will be denied without proper step therapy documentation.